Counterpoint Mutual Funds LLC Buys 4,688 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Counterpoint Mutual Funds LLC boosted its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 52.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,587 shares of the company’s stock after purchasing an additional 4,688 shares during the quarter. Counterpoint Mutual Funds LLC’s holdings in Castle Biosciences were worth $362,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Castle Biosciences by 147.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company’s stock worth $4,719,000 after purchasing an additional 98,571 shares during the period. Barclays PLC boosted its position in shares of Castle Biosciences by 310.7% during the 3rd quarter. Barclays PLC now owns 52,301 shares of the company’s stock valued at $1,491,000 after acquiring an additional 39,567 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Castle Biosciences by 165.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company’s stock valued at $1,980,000 after acquiring an additional 43,241 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Castle Biosciences by 16.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 274,761 shares of the company’s stock valued at $7,836,000 after acquiring an additional 39,417 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Castle Biosciences by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 624,683 shares of the company’s stock valued at $17,820,000 after acquiring an additional 7,004 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Stock Performance

Shares of NASDAQ CSTL opened at $20.03 on Tuesday. The stock has a market cap of $560.98 million, a price-to-earnings ratio of 100.16 and a beta of 0.98. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84. The stock’s 50-day moving average is $25.61 and its 200 day moving average is $28.56.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Stephens reiterated an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Robert W. Baird lifted their price target on Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences currently has an average rating of “Buy” and an average price target of $40.00.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of Castle Biosciences stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $29.14, for a total value of $229,244.38. Following the transaction, the director now directly owns 1,425 shares of the company’s stock, valued at $41,524.50. The trade was a 84.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Derek J. Maetzold sold 22,639 shares of Castle Biosciences stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $20.12, for a total value of $455,496.68. Following the completion of the transaction, the insider now directly owns 80,465 shares in the company, valued at $1,618,955.80. This trade represents a 21.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,204 shares of company stock valued at $1,055,988. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.